The intricacies of the tumor microenvironment (TME) are the primary reason PDAC resists immunotherapy.10,11 Accumulating evidence highlights the correlation between higher numbers of neoantigens, robust anti-tumor CD8 T cell responses, and enhanced long-term survival, as well as the clinical efficacy of immune checkpoint blockade strategies.12–15 For the induction of specific adaptive immune responses against tumors, neoantigens derived from tumor cells are captured by antigen-presenting cells (APCs) and efficiently processed and cross-presented to CD8 T cells. Here, CD8A is linked to neoplasm.